Skip to content

Clinical trials

Terminated Phase 2 Leukemia trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia Phase: Phase 2 Status: Terminated Clear all

126 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20016
20023
20033
20048
20058
200620
20074
20086
200912
20107
201111
20125
20132
20142
20154
20162
20173
20194
20202
20221
20231

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Terminated126

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center31
Masonic Cancer Center, University of Minnesota10
OHSU Knight Cancer Institute6
H. Lee Moffitt Cancer Center and Research Institute5
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins4
Fred Hutchinson Cancer Center3
National Cancer Institute (NCI)3
Novartis Pharmaceuticals3
Stanford University3
Brown University2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia126
Myelodysplastic Syndromes45
Lymphoma40
Leukemia, Lymphocytic, Chronic, B-Cell30
Leukemia, Myeloid, Acute30
Precursor Cell Lymphoblastic Leukemia-Lymphoma26
Leukemia, Myelogenous, Chronic, BCR-ABL Positive23
Multiple Myeloma20
Congenital Abnormalities16
Leukemia, Myeloid, Chronic-Phase16

Trials

Showing 1 to 25 of 126. Each trial links to its page on Pharma Observatory.

26 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.